| Literature DB >> 17226843 |
Florian Ertle1, Wolfgang Behnisch, Naima Ali Al Mulla, Mohammed Bessisso, Dietz Rating, Gunhild Mechtersheimer, Barbara Hero, Andreas E Kulozik.
Abstract
Opsoclonus-myoclonus-ataxia-syndrome (OMS) represents a rare neuroblastoma-associated paraneoplastic syndrome that commonly results in neurologic deficits despite tumor resection and immunosuppressive therapy. We describe the response of five such children to high-dose dexamethasone pulses including two patients in whom previous glucocorticoids, rituximab, and cytostatic drugs were not successful. All patients had MYCN non-amplified tumors that were detected 1 to 7 months after the onset of the OMS or ataxia. This treatment resulted in a good partial response in three and in complete remission in two patients. Our results show that dexamethasone pulses are likely to be useful for both, first-line- and salvage-therapy for OMS-patients. (c) 2007 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2008 PMID: 17226843 DOI: 10.1002/pbc.21107
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167